MedTech News

Type 1 diabetes isn’t an overnight attack against the body’s ability to make insulin. It can be a sustained campaign over years that relentlessly targets insulin-producing cells in the pancreas. Scientists have not fully understood why this autoimmune attack—when the body’s immune system mistakenly destroys its own healthy cells—persists so long rather than petering out.

Researchers from City of Hope have developed a new “plug-and-play” technology that adds engineered molecules to chimeric antigen receptor (CAR) T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. Published in Cancer Immunology Research, the preclinical study offers a more flexible way to help CAR T cells keep pace with mutating tumors.

A UCLA research team has engineered a new type of immune cell that attacks atherosclerotic plaques—the fatty buildup inside artery walls that drives most heart attacks and strokes. These engineered cells work by recognizing three harmful cell types within plaques. The paper is published in the journal Circulation Research.

E. coli in uncooked meat can cause diarrhea and food poisoning. Scientists, however, have found a way to turn the bacterium into a delivery agent that takes drugs straight to a tumor and transforms it into a tiny cancer drug dispensary.